55
Participants
Start Date
July 30, 2015
Primary Completion Date
May 30, 2016
Study Completion Date
May 30, 2016
Lebrikizumab
Lebrikizumab Dose Level 1 subcutaneous monotherapy was administered SC once every 4 weeks for a total of 3 doses.
Topical Corticosteroid Creams (Triamcinolone acetonide 0.1% and Hydrocortisone 2.5%)
Triamcinolone acetonide 0.1% cream will be supplied as single 454-g jars to be used on the body. Hydrocortisone 2.5% cream will be supplied as single 28-g tubes to be used on the face and intertriginous areas as indicated.
Sadick Research Group, New York
Montefiore Medical Center, The Bronx
Temple University Hospital, Philadelphia
Forward Clinical Trials, Tampa
Dermatology Specialists Research, LLC, Louisville
Respiratory Medicine Research; Institue of Michigan P.L.C., Ypsilanti
Center for Clinical Studies, Cypress
Allergy and Asthma Relief Experts, Granada Hills
T. Joseph Raoof Md, Inc., Encino
Allergy and Asthma Associates of Southern California - CRN, Mission Viejo
Oregon Medical Research Center, Portland
Asthma & Allergy Physicians of Rhode Island Clinical Research Institute (AAPRI CRI), Warwick
Dr. Lorne E. Albrecht Inc., Surrey
Skin Care Centre, Vancouver
Wiseman Dermatology Research Inc., Winnipeg
Guenther Research Inc., London
The Centre for Clinical Trials Inc., Oakville
York Dermatology Center, Richmond Hill
K. Papp Clinical Research Inc., Waterloo
Hoffmann-La Roche
INDUSTRY